Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PHGDH | O43175 | 8/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28013863 | 0.86 | MEN1 (0.47) | PTPN1PHGDHMCL1RXFP1MEN1 | |
| SCHEMBL2792109 | 0.85 | PHGDH (0.61) | PTPN1PHGDHCA12CA1CA2 | |
| SCHEMBL2565586 | 0.84 | MAPT (0.56) | PTPN1PHGDHKDM4EGRNSORT1 | |
| SCHEMBL1414029 | 0.84 | HDAC3 (0.56) | PTPN1PHGDHKDM4EGRNSORT1 | |
| SCHEMBL10957361 | 0.83 | CA12 (0.47) | PHGDHRXFP1MEN1KMT2ACA12 | |
| SCHEMBL4692622 | 0.83 | RXFP1 (0.47) | PTPN1PHGDHKDM4EGRNSORT1 | |
| SCHEMBL30722885 | 0.82 | PTPN1 (0.50) | PTPN1PHGDHKDM4EGRNSORT1 | |
| SCHEMBL4688310 | 0.81 | KDM4E (0.55) | PTPN1PHGDHKDM4EGRNSORT1 | |
| SCHEMBL2730926 | 0.81 | PHGDH (0.59) | PTPN1PHGDHMCL1KDM4EMEN1 | |
| SCHEMBL3435537 | 0.81 | PTPN1 (0.50) | PTPN1PHGDHKDM4EGRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104592116-B | 1,3,5-trisubstituted pyrazole compounds, and preparation method and application thereof | 山东大学 | 2017-01-11 | — | — | CN | claimed |
| CN-104592116-A | 1,3,5-trisubstituted pyrazole compounds, and preparation method and application thereof | UNIV SHANDONG | 2015-05-06 | — | — | CN | claimed |
| CN-104592116-B | 1,3,5-trisubstituted pyrazole compounds, and preparation method and application thereof | 山东大学 | 2017-01-11 | — | — | CN | disclosed |
| CN-104592116-A | 1,3,5-trisubstituted pyrazole compounds, and preparation method and application thereof | UNIV SHANDONG | 2015-05-06 | — | — | CN | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| EP-1685113-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005049578-A1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| US-4495195-A | ANTI-GOUT, ANTI-GOUTY ARTHRITIS AGENTS | ELI LILLY AND COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0112623-A2 | 3-Aryl-5-pyrazole-carboxylic-acid derivatives, their preparation and pharmaceutical compositions | ELI LILLY AND COMPANY (US) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | PTPN1 2086/4885PHGDH 1884/4885MCL1 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.